EP1812048A1 - Secretagogues de la gh et utilisations de ceux-ci - Google Patents
Secretagogues de la gh et utilisations de ceux-ciInfo
- Publication number
- EP1812048A1 EP1812048A1 EP05797145A EP05797145A EP1812048A1 EP 1812048 A1 EP1812048 A1 EP 1812048A1 EP 05797145 A EP05797145 A EP 05797145A EP 05797145 A EP05797145 A EP 05797145A EP 1812048 A1 EP1812048 A1 EP 1812048A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- group
- subject
- composition
- secretagogue
- trans
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000000580 secretagogue effect Effects 0.000 title claims abstract description 128
- 239000000203 mixture Substances 0.000 claims abstract description 202
- 150000002632 lipids Chemical class 0.000 claims abstract description 44
- 230000001925 catabolic effect Effects 0.000 claims abstract description 30
- 230000003247 decreasing effect Effects 0.000 claims abstract description 28
- 230000003920 cognitive function Effects 0.000 claims abstract description 24
- 230000002503 metabolic effect Effects 0.000 claims abstract description 24
- 230000002950 deficient Effects 0.000 claims abstract description 20
- 230000011164 ossification Effects 0.000 claims abstract description 18
- 230000036737 immune function Effects 0.000 claims abstract description 15
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 14
- 102000018997 Growth Hormone Human genes 0.000 claims description 219
- 108010051696 Growth Hormone Proteins 0.000 claims description 219
- 239000000122 growth hormone Substances 0.000 claims description 219
- 238000000034 method Methods 0.000 claims description 98
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 78
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 70
- 230000007423 decrease Effects 0.000 claims description 66
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 55
- 238000011282 treatment Methods 0.000 claims description 55
- 239000003795 chemical substances by application Substances 0.000 claims description 53
- 150000001413 amino acids Chemical group 0.000 claims description 50
- 239000003937 drug carrier Substances 0.000 claims description 50
- 206010049287 Lipodystrophy acquired Diseases 0.000 claims description 44
- 208000006132 lipodystrophy Diseases 0.000 claims description 44
- 230000004075 alteration Effects 0.000 claims description 36
- 235000012000 cholesterol Nutrition 0.000 claims description 34
- 239000008103 glucose Substances 0.000 claims description 34
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 32
- 239000003814 drug Substances 0.000 claims description 25
- 230000003187 abdominal effect Effects 0.000 claims description 24
- 238000007920 subcutaneous administration Methods 0.000 claims description 24
- 238000002360 preparation method Methods 0.000 claims description 20
- 208000008589 Obesity Diseases 0.000 claims description 18
- 235000020824 obesity Nutrition 0.000 claims description 18
- 229920001184 polypeptide Polymers 0.000 claims description 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 18
- 206010012601 diabetes mellitus Diseases 0.000 claims description 15
- 210000001596 intra-abdominal fat Anatomy 0.000 claims description 15
- 208000011580 syndromic disease Diseases 0.000 claims description 15
- 210000004003 subcutaneous fat Anatomy 0.000 claims description 14
- 210000001519 tissue Anatomy 0.000 claims description 14
- 230000032683 aging Effects 0.000 claims description 13
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 12
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 12
- 238000012217 deletion Methods 0.000 claims description 12
- 230000037430 deletion Effects 0.000 claims description 12
- 230000002209 hydrophobic effect Effects 0.000 claims description 12
- 210000004369 blood Anatomy 0.000 claims description 11
- 239000008280 blood Substances 0.000 claims description 11
- 208000006575 hypertriglyceridemia Diseases 0.000 claims description 11
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 11
- 208000030507 AIDS Diseases 0.000 claims description 10
- 206010062315 Lipohypertrophy Diseases 0.000 claims description 10
- 230000006872 improvement Effects 0.000 claims description 10
- 208000014674 injury Diseases 0.000 claims description 10
- 238000001356 surgical procedure Methods 0.000 claims description 10
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 10
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 9
- 206010020100 Hip fracture Diseases 0.000 claims description 9
- 206010022489 Insulin Resistance Diseases 0.000 claims description 9
- WAOQOSHNKJFOTO-BMGKTWPMSA-N hex-hgrf Chemical compound C([C@H](NC(=O)C/C=C/CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(N)=O)C1=CC=C(O)C=C1 WAOQOSHNKJFOTO-BMGKTWPMSA-N 0.000 claims description 9
- 238000001959 radiotherapy Methods 0.000 claims description 9
- 230000008733 trauma Effects 0.000 claims description 9
- 238000002512 chemotherapy Methods 0.000 claims description 8
- 208000020832 chronic kidney disease Diseases 0.000 claims description 8
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims description 8
- 238000002560 therapeutic procedure Methods 0.000 claims description 8
- 230000009278 visceral effect Effects 0.000 claims description 8
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 7
- 206010019280 Heart failures Diseases 0.000 claims description 7
- 238000007918 intramuscular administration Methods 0.000 claims description 7
- 238000001990 intravenous administration Methods 0.000 claims description 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 6
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims description 6
- 208000031886 HIV Infections Diseases 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 230000000840 anti-viral effect Effects 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- -1 hexenoyl Chemical group 0.000 claims description 6
- 239000003488 releasing hormone Substances 0.000 claims description 6
- 229920006395 saturated elastomer Polymers 0.000 claims description 6
- 230000000699 topical effect Effects 0.000 claims description 6
- 208000037357 HIV infectious disease Diseases 0.000 claims description 5
- 208000029725 Metabolic bone disease Diseases 0.000 claims description 5
- 206010049088 Osteopenia Diseases 0.000 claims description 5
- 208000001132 Osteoporosis Diseases 0.000 claims description 5
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 5
- 230000003387 muscular Effects 0.000 claims description 5
- 210000004899 c-terminal region Anatomy 0.000 claims description 4
- 230000001177 retroviral effect Effects 0.000 claims 1
- 239000000902 placebo Substances 0.000 description 82
- 229940068196 placebo Drugs 0.000 description 82
- QBEPNUQJQWDYKU-BMGKTWPMSA-N egrifta Chemical compound C([C@H](NC(=O)C/C=C/CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(N)=O)C1=CC=C(O)C=C1 QBEPNUQJQWDYKU-BMGKTWPMSA-N 0.000 description 51
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 29
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 28
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 26
- 230000000694 effects Effects 0.000 description 26
- 241000725303 Human immunodeficiency virus Species 0.000 description 24
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 20
- 230000035508 accumulation Effects 0.000 description 18
- 238000009825 accumulation Methods 0.000 description 18
- 230000008859 change Effects 0.000 description 18
- 108010010234 HDL Lipoproteins Proteins 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 13
- 210000003414 extremity Anatomy 0.000 description 13
- 101000825742 Homo sapiens Somatoliberin Proteins 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 102000004877 Insulin Human genes 0.000 description 10
- 108090001061 Insulin Proteins 0.000 description 10
- 208000001145 Metabolic Syndrome Diseases 0.000 description 10
- 229940125396 insulin Drugs 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 8
- 102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 description 8
- 208000035150 Hypercholesterolemia Diseases 0.000 description 8
- 101710142969 Somatoliberin Proteins 0.000 description 8
- 230000002411 adverse Effects 0.000 description 8
- 238000000540 analysis of variance Methods 0.000 description 8
- 238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000009286 beneficial effect Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000004936 stimulating effect Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- 102000004067 Osteocalcin Human genes 0.000 description 6
- 108090000573 Osteocalcin Proteins 0.000 description 6
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 210000000988 bone and bone Anatomy 0.000 description 6
- 102000004374 Insulin-like growth factor binding protein 3 Human genes 0.000 description 5
- 108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 description 5
- 206010027590 Middle insomnia Diseases 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 206010028289 Muscle atrophy Diseases 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 201000010390 abdominal obesity-metabolic syndrome 1 Diseases 0.000 description 4
- 238000011225 antiretroviral therapy Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000002591 computed tomography Methods 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 208000011661 metabolic syndrome X Diseases 0.000 description 4
- 201000000585 muscular atrophy Diseases 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000005867 T cell response Effects 0.000 description 3
- 101150033195 Victoria gene Proteins 0.000 description 3
- 210000000579 abdominal fat Anatomy 0.000 description 3
- 230000003178 anti-diabetic effect Effects 0.000 description 3
- 239000003472 antidiabetic agent Substances 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000008416 bone turnover Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000000546 chi-square test Methods 0.000 description 3
- 208000010877 cognitive disease Diseases 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- 230000002124 endocrine Effects 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 208000027061 mild cognitive impairment Diseases 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 201000009104 prediabetes syndrome Diseases 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 208000004611 Abdominal Obesity Diseases 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000006386 Bone Resorption Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010065941 Central obesity Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 241000845082 Panama Species 0.000 description 2
- 238000001358 Pearson's chi-squared test Methods 0.000 description 2
- 102100024819 Prolactin Human genes 0.000 description 2
- 108010057464 Prolactin Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 206010043268 Tension Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 230000001195 anabolic effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000037182 bone density Effects 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000000763 evoking effect Effects 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 230000002366 lipolytic effect Effects 0.000 description 2
- 238000009607 mammography Methods 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 238000007410 oral glucose tolerance test Methods 0.000 description 2
- 208000035824 paresthesia Diseases 0.000 description 2
- 239000000816 peptidomimetic Substances 0.000 description 2
- 238000011056 performance test Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 238000009597 pregnancy test Methods 0.000 description 2
- 229940097325 prolactin Drugs 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000007958 sleep Effects 0.000 description 2
- 230000003860 sleep quality Effects 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- YPMOAQISONSSNL-UHFFFAOYSA-N 8-hydroxyoctyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCCCCCCCO YPMOAQISONSSNL-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010005963 Bone formation increased Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101100315624 Caenorhabditis elegans tyr-1 gene Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 238000001134 F-test Methods 0.000 description 1
- 206010048474 Fat redistribution Diseases 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 208000005968 HIV-Associated Lipodystrophy Syndrome Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021067 Hypopituitarism Diseases 0.000 description 1
- 208000015580 Increased body weight Diseases 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 208000032912 Local swelling Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 101710084578 Short neurotoxin 1 Proteins 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000004490 abdominal subcutaneous fat Anatomy 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000011872 anthropometric measurement Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000798 anti-retroviral effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000001258 dyslipidemic effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000011902 gastrointestinal surgery Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 238000007446 glucose tolerance test Methods 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 208000029498 hypoalphalipoproteinemia Diseases 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 210000003692 ilium Anatomy 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003434 inspiratory effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 238000013439 planning Methods 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 208000032666 primary 1 hypoalphalipoproteinemia Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- WGWPRVFKDLAUQJ-MITYVQBRSA-N sermorelin Chemical compound C([C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)C1=CC=C(O)C=C1 WGWPRVFKDLAUQJ-MITYVQBRSA-N 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012384 transportation and delivery Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Definitions
- the invention relates to growth hormone (GH) secretagogues, such as GH releasing factor (GRF) and analogs thereof, and uses thereof.
- GH growth hormone
- GRF GH releasing factor
- Physiological systems include a number of lipid compounds/molecules such as triglycerides and sterols (e.g. cholesterol) , and associated carriers/complexes such as HDL, LDL, etc. Adverse levels or metabolism of such molecules is associated with related conditions such as fat accumulation, and associated disease.
- lipid compounds/molecules such as triglycerides and sterols (e.g. cholesterol)
- sterols e.g. cholesterol
- associated carriers/complexes such as HDL, LDL, etc.
- Adverse levels or metabolism of such molecules is associated with related conditions such as fat accumulation, and associated disease.
- Fat accumulation is observed in a range of conditions or syndromes such as obesity, metabolic syndrome, and the recently described HIV-related lipodystrophy syndrome. All these conditions include features which are known to increase the risk of diabetes and/or cardiovascular diseases.
- the metabolic syndrome also known as syndrome X, affect persons with frank obesity as well as those with an increased amount of abdominal fat, and is characterized by insulin resistance, dyslipidemia (hypertriglyceridemia, low serum HDL cholesterol levels, and increased LDL cholesterol levels) and hypertension.
- HIV-infected patients treated with highly active antiretroviral therapy commonly experience changes in fat distribution that include increased visceral and central fat accumulation (1) , as well as loss of extremity and subcutaneous fat (especially in the facial fat pads, limbs and buttocks) in association with insulin resistance and dyslipidemia (2, 3) .
- Recent data suggest increased cardiovascular disease and myocardial infarction rates in patients treated with prolonged antiretroviral therapy (ART) (4) .
- WHR waist to hip ratio
- central fat accumulation is related to increased metabolic risk indices .
- Growth Hormone is known for its lipolytic properties, and its potential role in reversing several of the body fat and associated metabolic abnormalities has been actively studied. Beneficial effects have been shown in GH- deficient individuals (Gotherstrom G. et al., J Clin Endocrinol Metab 2001 86 (10) :4657-4665) and non-HIV patients with abdominal obesity (Johannsson G, et al. , J Clin Endocrinol Metab 1997, 82 (3) : 727-734) .
- Cognitive abilities are impaired in a number of conditions including advancing age. Deleterious changes observed with aging affect particularly fluid intelligence, or abilities involving concept formation, rule discovery, planning behavior, and non-verbal reasoning. Conversely, crystallized intelligence, or abilities dependent upon accumulated experience and education is relatively resistant to age-related decline. It has . been suggested that the decline in GH and IGF-I observed with aging contribute to the impaired cognitive function.
- Immune Function Aging is accompanied by diminished circulating GH and IGF-I levels observed in parallel with a declined function of the immune system, particularly affecting the T- cell mediated immunity.
- the age-related T-cell immune deficiency has been partly attributed to a progressive atrophy of the thymus gland and is considered to be causally related to the increased risk and severity of acquired infections observed in the elderly.
- GH and IGF-I are known to play an integrating role in the development and function of the immune system, as endocrine and/or autocrine/paracrine factors, and their administration has been shown to reverse age-related immune changes .
- Immune enhancing effects of these factors have been investigated in other immune deficiency states and encouraging results have been observed in HIV-positive patients (Napolitano LA, et al., AIDS 2002 16 (8) :1103-1111) and in animal models of radiotherapy preceding bone marrow transplantation (Sun R, et al., BMT Meetings, Feb 22-26 Orlando, FL, Abstract 27 2002:68-69) .
- GH treatment increases muscle mass in older patients .
- the anabolic effects or abilities of GH to reverse or attenuate muscle wasting have been investigated in several patient groups.
- GH has been shown to improve nitrogen balance, an index of net whole-body protein balance, after major gastro-intestinal surgery, burn injury, or major trauma.
- Anabolic effects have been translated into clinical benefits in COPD patients
- the invention relates to GH secretagogues (e.g. GRF and analogs thereof) and uses thereof.
- the invention provides a method of altering a lipid parameter in a subject, said method comprising administering to said subject an agent selected from the group consisting of: (a) a growth hormone (GH) secretagogue; and (b) a composition comprising a GH secretagogue and a pharmaceutically acceptable carrier.
- an agent selected from the group consisting of: (a) a growth hormone (GH) secretagogue; and (b) a composition comprising a GH secretagogue and a pharmaceutically acceptable carrier.
- the invention provides a package comprising an agent selected from the group consisting of (a) a growth hormone (GH) secretagogue; and
- composition comprising a GH secretagogue and a pharmaceutically acceptable carrier; together with instructions for altering a lipid parameter in a subject.
- the invention provides a use of an agent selected from the group consisting of (a) a growth hormone (GH) secretagogue; and (b) a composition comprising a GH secretagogue and a pharmaceutically acceptable carrier; for altering a lipid parameter in a subject.
- an agent selected from the group consisting of (a) a growth hormone (GH) secretagogue; and (b) a composition comprising a GH secretagogue and a pharmaceutically acceptable carrier; for altering a lipid parameter in a subject.
- the invention provides a use of a growth hormone (GH) secretagogue for the preparation of a medicament for altering a lipid parameter in a subject.
- GH growth hormone
- the invention provides a method of altering a first body composition parameter of a subject, the method comprising administering to said subject an agent selected from the group consisting of (a) a growth hormone (GH) secretagogue; and (b) a composition comprising a GH secretagogue and a pharmaceutically acceptable carrier.
- an agent selected from the group consisting of (a) a growth hormone (GH) secretagogue; and (b) a composition comprising a GH secretagogue and a pharmaceutically acceptable carrier.
- the invention provides a package comprising an agent selected from the group consisting of: (a) a growth hormone (GH) secretagogue; and
- composition comprising a GH secretagogue and a pharmaceutically acceptable carrier; together with instructions for altering a first body composition parameter of a subject.
- the invention provides a use of an agent selected from the group consisting of: (a) a growth hormone (GH) secretagogue; and (b) a composition comprising a GH secretagogue and a pharmaceutically acceptable carrier; for altering a first body composition parameter of a subject.
- an agent selected from the group consisting of: (a) a growth hormone (GH) secretagogue; and (b) a composition comprising a GH secretagogue and a pharmaceutically acceptable carrier; for altering a first body composition parameter of a subject.
- the invention provides a use of a growth hormone (GH) secretagogue for the preparation of a medicament for altering a first body composition parameter of a subject.
- GH growth hormone
- the invention provides a method of treating a condition characterized by deficient or decreased bone formation in a subject, said method comprising administering to said subject an agent selected from the group consisting of: (a) a growth hormone (GH) secretagogue; and (b) a composition comprising a GH secretagogue and a pharmaceutically acceptable carrier.
- an agent selected from the group consisting of: (a) a growth hormone (GH) secretagogue; and (b) a composition comprising a GH secretagogue and a pharmaceutically acceptable carrier.
- the invention provides a package comprising an agent selected from the group consisting of: (a) a growth hormone (GH) secretagogue; and
- composition comprising a GH secretagogue and a pharmaceutically acceptable carrier; together with instructions for treating a condition characterized by- deficient or decreased bone formation in a subject.
- the invention provides a use of an agent selected from the group consisting of: (a) a growth hormone (GH) secretagogue; and (b) a composition comprising a GH secretagogue and a pharmaceutically acceptable carrier; for treating a condition characterized by deficient or decreased bone formation in a subject.
- a growth hormone (GH) secretagogue for the preparation of a medicament for treating a condition characterized by deficient or decreased bone formation in a subject.
- the invention relates to a method for (1) stimulating day-time vigilance and/or cognitive functions e.g. in conditions related to aging or mild cognitive impairment, (2) improving metabolic conditions associated with fat accumulation and/or hypercholesterolemia, (e.g.
- metabolic conditions including obesity, HIV-related lipodystrophy, metabolic syndrome or syndrome X
- (3) improving anabolism in catabolic/wasting conditions such as those observed in Chronic Renal Failure, congestive heart failure AIDS, following hip fracture, trauma, or major surgery, particularly in elderly subjects
- (4) improving immune function or reconstitution of immunodeficient states such as that associated aging, HIV or following high-dose chemotherapy and/or radiotherapy; the method comprising admininistering a GH secretagogue (e.g. GRF and analogs thereof) or a composition comprising a GH secretagogue and a pharmaceutically acceptable carrier; to a subject.
- a GH secretagogue e.g. GRF and analogs thereof
- a composition comprising a GH secretagogue and a pharmaceutically acceptable carrier
- the invention relates to uses of a GH secretagogue (e.g. GRF and analogs thereof) or a composition comprising a GH secretagogue and a pharmaceutically acceptable carrier, for (1) stimulating day-time vigilance and/or cognitive functions e.g. in conditions related to aging or mild cognitive impairment,
- a GH secretagogue e.g. GRF and analogs thereof
- a composition comprising a GH secretagogue and a pharmaceutically acceptable carrier
- metabolic conditions associated with fat accumulation and/or hypercholesterolemia e.g. metabolic conditions including obesity, HIV-related lipodystrophy, metabolic syndrome or syndrome X
- metabolic conditions associated with fat accumulation and/or hypercholesterolemia e.g. metabolic conditions including obesity, HIV-related lipodystrophy, metabolic syndrome or syndrome X
- anabolism in catabolic/wasting conditions such as those observed in
- the invention similarly relates to a package comprising an agent selected from the group consisting of: (a) a growth hormone (GH) secretagogue; and (b) a composition comprising a GH secretagogue and a pharmaceutically acceptable carrier; together with instructions for (1) stimulating day-time vigilance and/or cognitive functions (2) improving metabolic conditions associated with fat accumulation and/or hypercholesterolemia, (3) improving anabolism in catabolic/wasting conditions, and/or (4) improving immune function or reconstitution of immunodeficient states.
- GH growth hormone
- the invention similarly relates to a use of a GH secretagogue for the preparation of a medicament for (1) stimulating day-time vigilance and/or cognitive functions (2) improving metabolic conditions associated with fat ' accumulation and/or hypercholesterolemia, (3) improving anabolism in catabolic/wasting conditions, and/or (4) improving immune function or reconstitution of immunodeficient states.
- a GH secretagogue e.g. GRF compound or analog thereof
- the metabolic condition is associated with fat accumulation and/or hypercholesterolemia, e.g. obesity, HIV-related lipodystrophy, metabolic syndrome and syndrome X.
- hypercholesterolemia e.g. obesity, HIV-related lipodystrophy, metabolic syndrome and syndrome X.
- the catabolic condition is related to one selected from the group consisting of chronic renal failure, AIDS, hip fracture, trauma or major surgery in a subject.
- Fig. 1 illustrates the differences between treatment groups in changes from baseline to week 2 in the mean reaction time of the Continuous Performance Test (CPT) ;
- Fig. 2 illustrates changes from baseline to day 9 in Pz amplitude of evoked related potential (P300) during wakefulness;
- Fig. 3 illustrates mean AUC of antigen-specific proliferative T cell response;
- Fig. 4 illustrates the percentage of subjects with protective antibody titers (>l/40) for B/Victoria
- Fig. 5 illustrates the variation of mean IGF-I levels during time with placebo, 2mg/day TH9507, 0.5 mg/day TH9507 and lmg/day TH9507.
- Fig. 6 illustrates a flow diagram of patient disposition in respect of the studies described in Example 6.
- Fig. 7 illustrates results of dose response of TH9507 on A) IGF-I and B) truncal fat, as measured by DEXA, as described in Example 6.
- 7A "ng/ml” represents ng/ml of IGF-I as measured.
- 7B "kg” represents change in truncal fat, with the negative values indicating a decrease in truncal fat.
- Example 5 The studies described herein further demonstrate a beneficial effect of Th9507 on daytime vigilance and cognitive function (Example 2) , immune response (Example 3) , wasting/catabolic conditions (Example 4) and non-HDL cholesterol (Example 5) .
- the invention provides a method of altering a lipid parameter in a subject, said method comprising administering to said subject an agent selected from the group consisting of: (a) a growth hormone (GH) secretagogue; and (b) a composition comprising a GH secretagogue and a pharmaceutically acceptable carrier.
- the method results in no or substantially no increase in blood glucose levels in said subject.
- the invention provides a package comprising an agent selected from the group consisting of (a) a growth hormone (GH) secretagogue; and
- the invention provides a use of an agent selected from the group consisting of (a) a growth hormone (GH) secretagogue; and (b) a composition comprising a GH secretagogue and a pharmaceutically acceptable carrier; for altering a lipid parameter in a subject.
- GH growth hormone
- the above-mentioned alteration of a lipid parameter results in no or substantially no increase in blood glucose levels in said subject.
- the invention provides a use of a growth hormone (GH) secretagogue for the preparation of a medicament for altering a lipid parameter in a subject.
- GH growth hormone
- the above-mentioned alteration of a lipid parameter results in no or substantially no increase in blood glucose levels in said subject.
- the above-noted the alteration of a lipid parameter is selected from the group consisting of: (a) a decrease in cholesterol; (b) a decrease in non-HDL cholesterol; (c) a decrease in triglyceride; (d) a decrease in the ratio of total cholesterol:HDL cholesterol; and (e) any combination of (a) to (d) .
- the above-noted lipid parameter is associated with a condition selected from the group consisting of lipodystrophy, lipohypertrophy, obesity, dyslipidemia, hypertriglyceridemia and syndrome X.
- the invention provides a method of altering a first body composition parameter of a subject, the method comprising administering to said subject an agent selected from the group consisting of (a) a growth hormone (GH) secretagogue; and (b) a composition comprising a GH secretagogue and a pharmaceutically acceptable carrier.
- GH growth hormone
- the method results in no or substantially no decrease in a second body composition parameter of the subject, wherein the second body composition parameter is selected from the group consisting of: (i) limb fat; (ii) subcutaneous fat; (iii) subcutaneous abdominal tissue (SAT); and (iv) any combination of (i) to (iii) .
- the second body composition parameter is selected from the group consisting of: (i) limb fat; (ii) subcutaneous fat; (iii) subcutaneous abdominal tissue (SAT); and (iv) any combination of (i) to (iii) .
- the invention provides a package comprising an agent selected from the group consisting of: (a) a growth hormone (GH) secretagogue; and
- a composition comprising a GH secretagogue and a pharmaceutically acceptable carrier; together with instructions for altering a first body composition parameter of a subject.
- the above-mentioned alteration of a first body composition parameter results in no or substantially no decrease in a second body composition parameter of the subject, wherein the second body composition parameter is selected from the group consisting of (i) limb fat; (ii) subcutaneous fat; (iii) subcutaneous abdominal tissue (SAT) ; and (iv) any combination of (i) to (iii) .
- the invention provides a use of an agent selected from the group consisting of: (a) a growth hormone (GH) secretagogue; and (b) a composition comprising a GH secretagogue and a pharmaceutically acceptable carrier; for altering a first body composition parameter of a subject.
- a growth hormone (GH) secretagogue a growth hormone secretagogue
- a composition comprising a GH secretagogue and a pharmaceutically acceptable carrier
- the above- mentioned alteration of a first body composition parameter results in no or substantially no decrease in a second body composition parameter of the subject, wherein the second body composition parameter is selected from the group consisting of (i) limb fat; (ii) subcutaneous fat; (iii) subcutaneous abdominal tissue (SAT) ; and (iv) any combination of (i) to (iii) .
- the invention provides a use of a growth hormone (GH) secretagogue for the preparation of a medicament for altering a first body composition parameter of a subject.
- GH growth hormone
- the above-mentioned alteration of a first body composition parameter results in no or substantially no decrease in a second body composition parameter of the subject, wherein the second body composition parameter is selected from the group consisting of (i) limb fat; (ii) subcutaneous fat; (iii) subcutaneous abdominal tissue (SAT) ; and (iv) any combination of (i) to (iii) .
- the above-mentioned alteration of a first body composition parameter is selected from the group consisting of: (a) an increase in lean body mass,- (b) a decrease in trunk fat; (c) a decrease in visceral fat; (d) a decrease in abdominal girth; (e) a decrease in visceral abdominal tissue (VAT); (f) a decrease in VATrSAT ratio; and (g) any combination of (a) to (f) .
- the first body composition parameter is associated with a condition selected from the group consisting of lipodystrophy, lipohypertrophy, obesity, dyslipidemia, hypertriglyceridemia and syndrome X.
- the above-mentioned alteration of a first body composition parameter results in an improvement of quality of life of the subject.
- the invention provides a method of treating a condition characterized by deficient or decreased bone formation or for treating bone dysfunction or defect, in a subject, said method comprising administering to said subject an agent selected from the group consisting of: (a) a growth hormone (GH) secretagogue; and (b) a composition comprising a GH secretagogue and a pharmaceutically acceptable carrier.
- an agent selected from the group consisting of: (a) a growth hormone (GH) secretagogue; and (b) a composition comprising a GH secretagogue and a pharmaceutically acceptable carrier.
- the invention provides a package comprising an agent selected from the group consisting of: (a) a growth hormone (GH) secretagogue; and
- the invention provides a use of an agent selected from the group consisting of: (a) a growth hormone (GH) secretagogue; and (b) a composition comprising a GH secretagogue and a pharmaceutically acceptable carrier; for treating a condition characterized by deficient or decreased bone formation in a subject.
- an agent selected from the group consisting of: (a) a growth hormone (GH) secretagogue; and (b) a composition comprising a GH secretagogue and a pharmaceutically acceptable carrier; for treating a condition characterized by deficient or decreased bone formation in a subject.
- the invention provides a use of a growth hormone (GH) secretagogue for the preparation of a medicament for treating a condition characterized by deficient or decreased bone formation in a subject.
- GH growth hormone
- the above-noted condition characterized by deficient or decreased bone formation is selected from the group consisting of osteopenia and osteoporosis .
- the invention relates to uses of a GH secretagogue (e.g. GRF and analogs thereof) or a composition comprising a GH secretagogue and a pharmaceutically acceptable carrier, for (1) stimulating day-time vigilance and/or cognitive functions e.g. in conditions related to aging or mild cognitive impairment,
- metabolic conditions associated with fat accumulation and/or hypercholesterolemia e.g. metabolic conditions including obesity, HIV-related lipodystrophy, metabolic syndrome or syndrome X
- metabolic conditions associated with fat accumulation and/or hypercholesterolemia e.g. metabolic conditions including obesity, HIV-related lipodystrophy, metabolic syndrome or syndrome X
- anabolism in catabolic/wasting conditions such as those observed in Chronic Renal Failure, congestive heart failure AIDS, following hip fracture, trauma, or major surgery, particularly in elderly subjects
- immune function or reconstitution of immunodeficient states such as that associated aging, HIV or following high-dose chemotherapy and/or radiotherapy.
- the invention similarly relates to a package comprising an agent selected from the group consisting of: (a) a growth hormone (GH) secretagogue; and (b) a composition comprising a GH secretagogue and a pharmaceutically acceptable carrier; together with instructions for (1) stimulating day-time vigilance and/or cognitive functions (2) improving metabolic conditions associated with fat accumulation and/or hypercholesterolemia, (3) improving anabolism in catabolic/wasting conditions, and/or (4) improving immune function or reconstitution of immunodeficient states.
- GH growth hormone
- the invention similarly relates to a use of a GH secretagogue for the preparation of a medicament for (1) stimulating day-time vigilance and/or cognitive functions (2) improving metabolic conditions associated with fat accumulation and/or hypercholesterolemia, (3) improving anabolism in catabolic/wasting conditions, and/or (4) improving immune function or reconstitution of immunodeficient states.
- the above-mentioned lipodystrophy is HIV-related lipodystrophy.
- the above-mentioned subject is HIV-related lipodystrophy.
- the above-mentioned subject is receiving antiviral therapy.
- the above-mentioned subject suffers from a condition selected from the group consisting of diabetes, glucose intolerance and insulin resistance.
- the above-mentioned GH secretagogue is administered at a dose of about 0.0001 to about 4 mg, in a further embodiment, about 0.0001 to about ⁇ 2 mg, in a further embodiment, about 1 mg to about 2mg, in a further embodiment, about 1 mg and in a further embodiment, about 2 mg.
- the agent is administered by a route selected from the group consisting of intravenous, oral, transdermal, subcutaneous, mucosal, intramuscular, intranasal, intrapulmonary, parenteral, intrarectal and topical. In an embodiment, the agent is administered by a subcutaneous route.
- the subject is a mammal, in a further embodiment, a human.
- analog is intended to mean a molecule of different structure but having a biological function similar to the structures of the GRF or to a biologically functional fragment thereof which may include peptidomimetics. Peptidomimetics may be conveniently prepared by direct chemical synthesis using methods well known in the art.
- subject is intended to mean any mammal including, but not limited to, human, canine, feline, equine, caprine, bovine, porcine and ovine.
- cogntive function is intended to mean functions including, but not limited to thinking, reasoning, memory and problem solving.
- catabolic/wasting conditions is intended to mean condition including, but not limited to, frail bones, low muscular mass and muscle wasting.
- the compound identified as TH9507 is the [hexenoyl-trans-3-Tyrl] hGRF(1- 44)NH 2 .
- the methods and corresponding uses and packages described herein comprise administering to a subject a growth hormone (GH) secretagogue.
- GH secretagogue refers to any compound or molecule, natural or synthetic, which may result in, either directly or indirectly, GH secretion and/or an increase in GH secretion.
- the GH secretagogue is a growth hormone-releasing factor (GRF; also referred to as growth hormone releasing hormone [GHRH] ) or GRF analog.
- GRF growth hormone-releasing factor
- the GRF is human GRF (hGRF) .
- hGRF Human growth hormone-releasing factor
- amino acid sequence of the just- noted 44 amino acid form is as follows:
- the minimum active core comprises the first 29 amino acids of the above sequence, which is referred to herein as hGRF(1-29)NH 2 , and has the following structure:
- the 1-44 and 1-29 forms differ in that the 1-44 form contains the following additional amino acids, which correspond to positions 30-44 of the 1-44 form:
- the above-mentioned GRF analog is a GRF analog of formula A:
- Al is Tyr or His,-
- A2 is VaI or Ala
- A8 is Asn or Ser
- A13 is VaI or lie
- A15 is Ala or GIy; Al8 is Ser or Tyr; A24 is GIn or His ;
- A25 is Asp or GIu; A27 is Met, lie or NIe; A28 is Ser or Asn; A30 is a bond or amino acid sequence of 1 up to 15 residues; and
- X is a hydrophobic tail anchored via an amide bond to the N-terminus of the peptide and the hydrophobic tail defining a backbone of 5 to 7 atoms;
- backbone can be substituted by Cl-6 alkyl, C3-6 cycloalkyl, or C6-12 aryl and the backbone comprises at least one rigidifying moiety connected to at least two atoms of the backbone;
- said moiety selected from the group consisting of double bond, triple bond, saturated or unsaturated C3-9 cycloalkyl, and C6-12 aryl.
- X noted above is selected from the group consisting of:
- A30 noted above is selected from the group consisting of:
- the above-noted GRF peptide is selected from the group consisting of:
- the above- mentioned GH secretagogue may be used therapeutically in formulations or medicaments to effect the above-noted alterations and to prevent or treat the above-noted conditions.
- the invention provides corresponding methods of medical treatment, in which a therapeutic dose of a GH secretagogue is administered in a pharmacologically acceptable formulation, e.g. to a patient or subject in need thereof.
- the invention also provides therapeutic compositions comprising a GH secretagogue and a pharmacologically acceptable excipient or carrier.
- such compositions include GH secretagogue in a therapeutically or prophylactically effective amount sufficient to effect the above-noted alterations and to treat the above-noted conditions.
- the therapeutic composition may be soluble in an aqueous solution at a physiologically acceptable pH.
- a “therapeutically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result, such as to effect the above-noted alterations and to reduce the progression of the above-noted conditions.
- a therapeutically effective amount of a GH secretagogue may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the compound to elicit a desired response in the individual. Dosage regimens may be adjusted to provide the optimum therapeutic response.
- a therapeutically effective amount is also one in which any toxic or detrimental effects of the compound are outweighed by the therapeutically beneficial effects.
- a prophylactically effective amount refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result, such as preventing or inhibiting the rate of onset or progression of the above- noted conditions .
- a prophylactically effective amount can be determined as described above for the therapeutically effective amount. For any particular subject, specific dosage regimens may be adjusted over time according to the individual need and the professional judgement of the person administering or supervising the administration of the compositions .
- pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible.
- the carrier is suitable for parenteral administration.
- the carrier can be suitable for intravenous, intraperitoneal, intramuscular, subcutaneous, sublingual or oral administration.
- Pharmaceutically acceptable carriers include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the pharmaceutical compositions of the invention is contemplated. Supplementary active compounds can also be incorporated into the compositions.
- compositions typically must be sterile and stable under the conditions of manufacture and storage.
- the composition can be formulated as a solution, microemulsion, liposome, or other ordered structure suitable to high drug concentration.
- the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like) , and suitable mixtures thereof.
- the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
- isotonic agents for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition.
- Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, monostearate salts and gelatin.
- a GH secretagogue can be administered in a time release formulation, for example in a composition which includes a slow release polymer.
- the active compounds can be prepared with carriers that will protect the compound against rapid release, such as a controlled release formulation, including implants and microencapsulated delivery systems.
- Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, polylactic acid and polylactic, polyglycolic copolymers (PLG) .
- PLG polylactic, polyglycolic copolymers
- Sterile injectable solutions can be prepared by- incorporating the active compound (e.g. a GH secretagogue ) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization.
- dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above.
- a sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
- a GH secretagogue may be formulated with one or more additional compounds that enhance its solubility.
- compositions of the present invention comprising a GH secretagogue
- a GH secretagogue may be provided in containers, kits or packages (e.g. commercial packages) which further comprise instructions for its use to effect the above-noted alterations and to prevent or treat the above-noted conditions.
- the invention further provides a package comprising a GH secretagogue or the above-mentioned composition together with instructions to effect the above- noted alterations and to prevent or treat the above-noted conditions.
- the invention further provides a use of a GH secretagogue to effect the above-noted alterations and to prevent or treat the above-noted conditions.
- the invention further provides a use of a GH secretagogue for the preparation of a medicament to effect the above-noted alterations and to prevent or treat the above-noted conditions.
- hexenoyl trans-3)hGRF(1-44)NH 2 (also referred to as TH9507 herein) , which is a synthetic human growth hormone releasing factor analog that comprises the 44-amino acid sequence of human growth hormone releasing factor (hGRF) on which a hexenoyl moiety, a C6 side chain has been anchored on Tyr 1 at the n-terminal.
- hGRF human growth hormone releasing factor
- Th9507 The in vitro half-life of Th9507 is 3-8 hours compared to 0.56 hours for hGRF. Daily 1 and 2 mg doses have been shown to increase IGF-I to the physiological range seen in younger adults (14) . The safety profile of TH9507 is generally good. Th9507 has been studied in patients with Type II DM, and was not shown to aggravate overall glycemic control when administered at a daily dose up to 2 mg (15) .
- Example 2 Administration of TH9507 for improving daytime vigilance in subjects with sleep maintenance insomnia
- the present example shows the effect of a 14 day- administration of 2 doses of TH9507 (0.1 mg and 1 mg) on vigilance parameters in subjects of 35 to 50 years of age exhibiting sleep maintenance insomnia.
- TH9507 0.1 mg and 1 mg
- CPT Continuous Performance Test
- the Mean Reaction Time of the CPT was significantly and markedly decreased in the 0.1 mg group when compared to placebo.
- No significant effect was observed in the 1 mg group.
- Circulating IGF-I and IGFBP-3 levels were significantly increased at week 2 in the 1 mg group when compared to placebo (P ⁇ 0.0001, ANOVA on changes from baseline) .
- TH9507 was administered daily for 7 days in a cross-over design. This study involved 12 healthy subjects aged between 50 to 65 years, exhibiting age-related sleep impairment (Pittsburgh Sleep Quality Index Score from 3 to 7) . At the end of the treatment period, daytime vigilance was significantly enhanced when compared to placebo in subjects receiving 1 mg of TH9507, as assessed by P300, an event-related potential test.
- TH9507 improves daytime vigilance in sleep maintenance insomnia in subjects and would favor a direct mechanism of action of TH9507, not mediated by IGF-I.
- Data are supported by those obtained by Vitiello et al (Vitiello M.V., et al., Gerontologist 2002 40 (Special Issue 1) :39-N/A. using hGRF in cognitive tests involving psychomotor and perceptual processing speed (Deijin JB et al, Psychoneuroendocrinology 1998 23(l) :45-55) and may support further clinical investigations in subjects with impaired cognitive functions.
- Example 3 Effects of TH9507 on the immune response to influenza vaccination in elderly subjects
- the present example describes immune findings following an influenza vaccination challenge in elderly subjects.
- the proliferative T cell response was assessed by a mitogen assay using tritiated thymidine ( 3 H) incorporation and results were log-base 10 transformed prior to analysis.
- the antibody titers were determined by standard hemaglutinaion inhibition assay and results were log-base 2 transformed prior to analysis.
- administration of TH9507 increased the proportion of patients achieving a protective antibody level for the Victoria antigen when compared to placebo.
- TH9507 has a therapeutic potential in immune indications.
- its effect of the T- lymphocyte proliferation response following vaccination makes it attractive to develop in. clinical situations where the cell-mediated immune system is depressed, such as viral infections in the elderly and immune-deficient states following HIV infection, high-dose chemotherapy or radiotherapy.
- Example 4 ThGRF's benefits in wasting/catabolic conditions
- the present example shows the effect of a 7-day administration of TH9507 on circulating IGF-I levels in healthy middle-aged men.
- the study used a randomized, double-blind, placebo-controlled design and was conducted in healthy men, aged 50 to 60 years old. Subjects (8 per group) were injected S.C. once a day for 7 consecutive days with placebo, 0.5, 1 or 2 mg of TH9507. Circulating IGF-I levels were measured on Days 1 to 7. The 12 hour GH response and TH9507 PK profile were determined on Day 1 and 7.
- IGF-I increased over baseline values by 8% (placebo) , 37% (0.5 mg) , 89% (lmg) and 106% (2 mg) ; these increases were statistically significant for all 3 doses of TH9507.
- the 1 mg and 2 mg doses were equally potent and induced a doubling of IGF-I levels up to levels expected for young adults (286 + 25 and 284 + 55 ng/ml, respectively) , none of the subjects exhibited levels greater than 400 ng/ml. A plateau was reached at Day 4 and 6 for the 1 mg and 2 mg doses, respectively.
- GH response to TH9507 increased rapidly both on
- PK analysis indicated that Cmax and AUC parameters increased in function of the dose administered.
- the half-life of the TH9507 ranged between 2 and 5 hours.
- the present example illustrates beneficial effects of TH9507 on non-HDL cholesterol levels in a diabetic population.
- HbAIc glycosylated hemoglobin
- Example 6 Effect of GRF analog on lipid profile, body composition and quality of life in HIV-infected patients
- Body composition was assessed by DXA and abdominal CT scan; IGF-I, insulin, glucose, lipid, bone turnover, immunologic, and safety parameters.
- Treatment with TH9507 resulted in a dose-related increase in serum IGF-I levels within the physiological range [18 (32) ng/mL, 87 (67) ng/mL, 123 (79) ng/mL, mean (SD) for placebo, lmg, 2 mg, respectively, P ⁇ 0.01 for change in each active group vs . placebo] .
- Lean body mass increased significantly in both treatment groups compared to placebo [-0.5 (1.6) kg, 0.7 (2.0) kg, and 1.7 (2.3) kg; placebo, lmg, 2 mg, respectively; P ⁇ 0.01 for 2 mg dose vs. placebo, P ⁇ 0.05 for the 1 mg group vs. placebo] .
- TH9507 effectively improved body composition and reduced truncal fat by preferentially decreasing visceral fat while preserving subcutaneous fat in patients with HIV lipodystrophy. TH9507 did not increase glucose levels, even among those with impaired glucose tolerance or diabetes mellitus at baseline, and improved the lipid profile. These data suggest that TH9507, a GRF analog, may be a beneficial treatment strategy for HIV lipodystrophy.
- Subjects receiving testosterone or estrogen within the prior six months, with known drug or alcohol dependence or who had participated in another clinical trial with an investigational agent within 30 days were also excluded from the study. All subjects were required to be on a stable antiretroviral regimen for 8 weeks prior to enrollment. Subjects receiving lipid lowering medications were required to be on a stable regimen for 3 months prior to enrollment. Subjects were not permitted to begin antidiabetic medication, use systemic corticosteroids for > 10 days, or begin estrogen or testosterone preparations during the study.
- Study Procedures Subjects underwent a screening visit to determine eligibility. All subjects gave written consent to participate in the study, and the study was approved by the Institutional Review Board at each participating site. BMI, anthropometic measurements, TSH and prolactin were performed. Viral load and CD4 count were performed if not previously done within 8 weeks of the study. A PSA was performed in male subjects and a pregnancy test was performed in female subjects. Mammography was also performed in female subjects if not previously done within 6 months of the study.
- anthropometric measurements were obtained. Total body lean and fat mass as well as regional fat mass in the trunk and extremities were assessed by DEXA. Abdominal subcutaneous and visceral fat area and the ratio of VAT to SAT were determined by cross-sectional CT at L4- L5. Biochemical parameters including insulin-like growth factor-I, glucose, insulin, lipid profile (cholesterol, HDL, LDL, triglyceride, non HDL and the ratio of cholesterol:HDL) , free fatty acids, HbAlC, IGFBP-3, and bone markers (serum osteocalcin and NTX-I) , CD4, viral load, and a pregnancy test for female subjects were determined in the fasting state. In addition, insulin and glucose response to a 75 gram standard glucose challenge were assessed and a quality of life questionnaire was administered.
- Each vial was reconstituted with sterile water immediately prior to injection. Patients were instructed to inject each AM at approximately 0900 h.
- Serum IGF-I was measured after acid-ethanol extraction using the Esoterix RIA kit (Esoterix Inc., Calabasas Hill, CA) , with a sensitivity of 10 ng/mL. Intra- and inter-assay coefficients of variation were 4.6-20% and 9-10%, respectively. Serum IGFBP-3 was measured using the Esoterix RIA kit (Esoterix Inc., Calabasas Hill, CA) with a sensitivity of 0.3 mg/mL. Intra- and inter-assay coefficients of variation were 5.1-13% and 5.5-17%, respectively.
- HDL, LDL, total cholesterol, triglycerides and FFA were determined by enzymatic colorimetric assay.
- Glucose was measured by enzymatric test (Gluco-quant®, Roche diagnostics, Indianapolis, IN) .
- HbAIc was determined by chromatography.
- PSA was determined using the Hybritech®PSA test (Beckman Coulter, Mississauga, Canada) .
- TSH was measured by microparticle enzyme immunoassay (AxSYM hTSH II, Abbott Laboratories, Abbott Park, IL) .
- NTX N-terminal telopeptide of type I collagen; a bone resorption marker
- Osteocalcin was measured using a commercially available enzymatic immunoassay kit (MetraTM osteocalcin, Quidel Corporation, San Diego, CA) . CD4 and viral load were performed by the individual site labs by routine methodology. HOMA was calculated as : ⁇ Insulin (30min- Omin)
- Body composition endpoints included trunk fat and trunk to limb fat ratio by DEXA and VAT and VAT:SAT by CT scan. Other endpoints included IGF-I, lipid parameters, glucose and insulin, CD4, viral load, bone markers, and quality of life.
- a sample size of 20 patients/group was planned to assess a statistically significant change of 10% or more in intra-group analyses . The planned dropout rate was 25% and therefore 60 patients were enrolled into the study.
- Baseline data are compared between the groups by F- test based on ANOVA for continuous variables and Chi-Square test for categorical variables. Change over time between groups is compared by ANOVA or the Chi-Square test. Where appropriate, data were rank transformed prior to analysis. Changes within each group are determined by t-test.
- the ITT (intent to treat) population is defined as all subjects who received at least one dose of the study treatment. Descriptive statistics and analyses for all efficacy and safety analyses are performed on the ITT population. End of study, 12 week, data are used to calculate changes in body composition. For biochemical indices, the last observation available is used to calculate change. Imputation for missing data is not performed. For body composition, end of study data are used to calculate change. Interim analyses were not performed. Results are mean (SD) unless otherwise noted. All statistical tests were performed with a two-sided Type I error level of 0.05.
- Baseline demographic for the three study groups are shown in Table 3. At baseline no significant differences were seen between the groups except, including use of antiretroviral therapy. The percentage of patients with diabetes (fasting glucose ⁇ 7.0 mmol/L or 2h-glucose ⁇ 11.1 mmol/L) and impaired glucose tolerance (6.1 mmol/L ⁇ fasting glucose ⁇ 6.9 mmol/L or 7.8 mmol/L ⁇ 2h-glucose ⁇ 11.1 mmol/L) was not different between the groups. Among the entire study group, 23% of subjects demonstrated IGT and 5% demonstrated diabetes mellitus at baseline.
- Data are mean (SD) .
- BMI body-mass index
- WHR waist/hip ratio
- WC waist circumference
- IGF-I increased significantly with the 1 and 2 mg dose compared to placebo [18 (32) ng/mL, 87 (67) ng/mL, 123 (79) ng/mL, placebo, 1 mg 2mg, respectively, P ⁇ 0.01 for each active group vs. placebo] ( Figure 3) .
- Triglyceride levels decreased in the 2 mg group compared to placebo (-0.2 (1.3) , -0.9 (4.2) , -0.9 (1.2) , last observation values for placebo, 1 mg, 2 mg, respectively, P ⁇ 0.05) and the ratio of cholesterol to HDL improved in both treatment groups compared to placebo (0.3 (1.1), -0.3 (0.7) , -0.3 (0.6) , last observation values for placebo, 1 mg, 2 mg, respectively, P ⁇ 0.05) .
- Baseline Baseline ⁇ Baseline ⁇ Baseline ⁇ 2 me f VS . P 1 mg vs . P
- Trunk Fat (kg) 14.6(3.4) 0.1(1.1) 13.1(3.4) -0.5(1.4) 12.2(4.6) -1.1(1.3)* 0.0144 0.1782
- VAT SAT 0.89(0.50) -0.01(0.10) 1.17(1.25) -0.23(0.47)* 1.12 (0.74) -0.14 (0.18)* ' 0.0084 0.0434
- IGF-I (ng/raL) 132.4(42.4) 18.3(31.7) 165.3(62.3) 87.5 (66.9) * 157.0 (41.4) 122.6(79.1)* 0.0002 0.0042
- IGFBP-3 (Mg/L) 2.7(0.7) 0.1(0.4) 2.9(0.9) 0.6(0.7)*2. 9(0.4) 0.6(0.5) * 0.0007
- NTX (nMBCE/ ⁇ iM) 36 .3 (17. 7) -0. 8(20.8) 37 .1(13. 4) 4.5 (24.9) 37 .2(23. D -I 3.5(27.7) 1. 0000 1.0000
- a health-related quality of life questionnaire (PLC, Quality of Life Profile for the Chronocally 111) was self-administered to 61 patients randomized to receive placebo or TH9507 at 1 or 2 mg s.c. daily.
- the PLC questionnaire included a general, non-specific part assessing 6 dimensions of global health as well as a disease specific part capturing impact of enlarged abdominal girth, abdominal bloating, tenseness and pain, as well as diarrhea, visible facial changes, visible changes in physical appearance, and the feeling of being recognized as an HIV positive person.
- Study population included 54 men and 7 women. Baseline mean age was 46 + 7 [SD] , BMI 28 + 3 [SD] kg/m 2 , WC 102 cm ⁇ 8 [SD] and WHR 1.0 ⁇ 0.1 [SD] . No significant difference between groups was noted for subscales of the main portion of the PLC. Slight changes were observed within the treated groups in the positive mood and social well- being scores but were not considered clinically significant.
- Discontinuation rates were not different between the groups (24%, 11%, 29%, placebo, 1 mg, 2 mg respectively) .
- One subject in the placebo group arthritis
- none in the 1 mg group and 3 in the 2 mg group rash, arhtralgia, paresthesia
- Severe AE' s were reported in 6% of the placebo group, 13% of the 1 mg group and 10% of the 2 mg group.
- Musculoskeletal AE's e.g. pain and arthralgias were noted in 24%, 26% and 29% of subjects in the placebo, 1 mg and 2 mg groups respectively.
- Carpal tunnel symptoms were not noted in any patient. Edema and/or peripheral swelling were noted in 1 patient in the 2 mg group only.
- Visceral fat also decreased significantly by more than 15% over 3 months within the 2 mg group.
- the magnitude of this change on a percentage basis is equivalent to that seen with pharmacologic doses of GH (9) , suggesting that this strategy is highly effective and potentially very useful because of the general lack of side effects associated with physiologic increases in GH.
- the 2mg GRF dose significantly improved triglyceride levels and the cholesterol to HDL ratio.
- Similar beneficial effects on triglyceride were seen with lower, alternating day, but not higher doses of GH in a study reported by Kotler et al .
- Growth hormone has been shown to decrease cholesterol and triglycceride levels in GH deficient patients and among otherwise healthy men chosen for abdominal obesity (19, 20) .
- our data suggest that treatment with TH9507 resulted in an improved lipid profile in dyslipidemic, abdominally obese patients with HIV lipodystrophy.
- TH9507 was also associated with other benefits in this study. Osteocalcin, a marker of bone formation increased within the 2 mg group, whereas NTX, a marker of bone resorption did not suggesting a net positive effect on bone turnover. Reduced bone density has been described among patients with HIV disease and among those with lipodystrophy, in inverse association with visceral and truncal adiposity (25, 26) . Growth hormone is well known to stimulate bone formation (27) . Relative reductions in GH secretion may therefore contribute to reduced bone density in some patients with lipodystrophy and a positive effect on bone formation, with physiologic increases in GH is an additional benefit of TH9507.
- TH9507 A new Growth Hormone-Releasing Factor (GRF) analogue is a powerful Insulin-like Growth Factor-1 (IGF-I) inducer in 50-60 years old healthy subjects : A 7-Day, Randomizeed Multidose Study. In: The Endocrine Society's 84 rd Annual Meeting; 2001; Denver; 2001. p. P2-292. 15. Clemmons D, Miller S, De Villers A, et al. Safety assessment and metabolic effects of TH9507, a Growth Hormone Releasing Factor analog(GRF) in patients with Type 2 diabetes mellitus. In: The Endocrine Society's 86 Annual Meeting; 2003; Philadelphia; 2003. p. P2-354. 16.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Child & Adolescent Psychology (AREA)
- Communicable Diseases (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/969,463 US7316997B2 (en) | 2003-05-29 | 2004-10-20 | GH secretagogues and uses thereof |
CA2485472A CA2485472C (fr) | 2004-10-20 | 2004-10-20 | Secretagogues a hormone de croissance et leurs utilisations |
PCT/CA2005/001611 WO2006042408A1 (fr) | 2004-10-20 | 2005-10-20 | Secretagogues de la gh et utilisations de ceux-ci |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1812048A1 true EP1812048A1 (fr) | 2007-08-01 |
EP1812048A4 EP1812048A4 (fr) | 2012-01-18 |
Family
ID=36202645
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP05797145A Withdrawn EP1812048A4 (fr) | 2004-10-20 | 2005-10-20 | Secretagogues de la gh et utilisations de ceux-ci |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1812048A4 (fr) |
JP (1) | JP2008516994A (fr) |
KR (1) | KR101228229B1 (fr) |
AU (1) | AU2005297366B2 (fr) |
NO (1) | NO20072136L (fr) |
WO (1) | WO2006042408A1 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2430067T3 (es) | 2007-03-28 | 2013-11-18 | President And Fellows Of Harvard College | Polipéptidos cosidos |
RU2009140731A (ru) * | 2007-04-04 | 2011-05-10 | Тератекнолоджиз Инк. (Ca) | Фармацевтические составы, содержащие молекулы ghrh |
WO2012021874A1 (fr) | 2010-08-13 | 2012-02-16 | Aileron Therapeutics, Inc. | Macrocycles peptidomimétiques à coupleurs thioéther |
MX2013012259A (es) | 2011-04-21 | 2013-11-22 | Theratechnologies Inc | Analogos del factor de liberacion de la hormona de crecimiento (grf) y usos de estos. |
BR112014009418A2 (pt) | 2011-10-18 | 2017-04-18 | Aileron Therapeutics Inc | macrociclos peptidomiméticos |
EP2819688A4 (fr) | 2012-02-15 | 2015-10-28 | Aileron Therapeutics Inc | Macrocycles peptidomimétiques réticulés par triazole et par thioéther |
AU2013221432B2 (en) | 2012-02-15 | 2018-01-18 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
JP6526563B2 (ja) | 2012-11-01 | 2019-06-05 | エイルロン セラピューティクス,インコーポレイテッド | 二置換アミノ酸ならびにその調製および使用の方法 |
CA2961258A1 (fr) | 2014-09-24 | 2016-03-31 | Aileron Therapeutics, Inc. | Macrocycles peptidomimetiques et leurs utilisations |
CN107614003A (zh) | 2015-03-20 | 2018-01-19 | 艾瑞朗医疗公司 | 拟肽大环化合物及其用途 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6458764B1 (en) * | 1995-05-26 | 2002-10-01 | Theratechnologies Inc. | GRF analogs with increased biological potency |
US6696063B1 (en) | 1998-12-30 | 2004-02-24 | Applied Research Systems Ars Holding N.V. | Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy |
US6518292B1 (en) * | 1999-03-12 | 2003-02-11 | Bristol-Myers Squibb Co. | Heterocyclic aromatic compounds usefuls as growth hormone secretagogues |
AU2003229222B2 (en) * | 2003-05-29 | 2009-11-12 | Theratechnologies Inc. | GRF analog compositions and their use |
CA2542433A1 (fr) * | 2003-10-20 | 2005-04-28 | Theratechnologies Inc. | Utilisation d'analogues de somatostatine dans le traitement de patients souffrant de cachexie |
-
2005
- 2005-10-20 WO PCT/CA2005/001611 patent/WO2006042408A1/fr active Application Filing
- 2005-10-20 KR KR1020077011178A patent/KR101228229B1/ko active IP Right Grant
- 2005-10-20 AU AU2005297366A patent/AU2005297366B2/en active Active
- 2005-10-20 EP EP05797145A patent/EP1812048A4/fr not_active Withdrawn
- 2005-10-20 JP JP2007537087A patent/JP2008516994A/ja active Pending
-
2007
- 2007-04-24 NO NO20072136A patent/NO20072136L/no not_active Application Discontinuation
Non-Patent Citations (2)
Title |
---|
DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; August 2003 (2003-08), ABRIBAT T ET AL: "TH9507, a growth hormone-releasing factor analogue (GRF), does not impair overall glucose control and decreases non-HDL cholesterol in patients with Type 2 diabetes.", XP002665112, Database accession no. PREV200400013130 * |
See also references of WO2006042408A1 * |
Also Published As
Publication number | Publication date |
---|---|
JP2008516994A (ja) | 2008-05-22 |
KR20070069207A (ko) | 2007-07-02 |
AU2005297366B2 (en) | 2011-12-08 |
EP1812048A4 (fr) | 2012-01-18 |
WO2006042408A1 (fr) | 2006-04-27 |
KR101228229B1 (ko) | 2013-01-31 |
AU2005297366A1 (en) | 2006-04-27 |
NO20072136L (no) | 2007-07-16 |
WO2006042408A9 (fr) | 2007-05-24 |
AU2005297366A2 (en) | 2006-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8314066B2 (en) | GH secretagogues and uses thereof | |
AU2005297366B2 (en) | GH secretagogues and uses thereof | |
USRE40850E1 (en) | Analogs of parathyroid hormone | |
US7410948B2 (en) | Analogs of parathyroid hormone | |
JP4008825B2 (ja) | 副甲状腺ホルモンの類似体 | |
RU2130463C1 (ru) | Аналог-агонист амилина, его фармацевтически приемлемые соли, композиция, проявляющая свойства агониста амилина | |
EP1104438B1 (fr) | Nouveaux peptides antidiabetiques | |
KR100497709B1 (ko) | 부갑상선 호르몬의 동족체 | |
US7910548B2 (en) | Methods for treating obesity | |
WO1996032126A1 (fr) | Analogues du facteur liberant l'hormone de croissance | |
CA2485472C (fr) | Secretagogues a hormone de croissance et leurs utilisations | |
RU2157699C2 (ru) | Пептиды, обладающие сродством к рецептору паратгормона (ртн) и стимулирующие активность аденилатциклазы |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20070502 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK YU |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 3/00 20060101ALI20111208BHEP Ipc: A61P 37/00 20060101ALI20111208BHEP Ipc: A61K 38/25 20060101AFI20111208BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20111216 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20140305 |